Analysts See $-0.54 EPS for Natera, Inc. (NTRA); Bellatrix Exploration Ltd. (BXE) Had 4 Bulls

May 3, 2018 - By Pete Kolinski

Natera, Inc. (NASDAQ:NTRA) Logo

Among 5 analysts covering Bellatrix Exploration Ltd (NYSE:BXE), 4 have Buy rating, 1 Sell and 0 Hold. Therefore 80% are positive. Bellatrix Exploration Ltd had 11 analyst reports since July 21, 2015 according to SRatingsIntel. National Bank Canada maintained Bellatrix Exploration Ltd. (NYSE:BXE) on Friday, November 6 with “Outperform” rating. The stock of Bellatrix Exploration Ltd. (NYSE:BXE) has “Hold” rating given on Monday, August 10 by Zacks. The firm earned “Buy” rating on Friday, November 10 by Northland Capital. BMO Capital Markets initiated the stock with “Sell” rating in Thursday, January 11 report. The rating was maintained by Northland Capital on Monday, December 11 with “Buy”. See Bellatrix Exploration Ltd. (NYSE:BXE) latest ratings:

11/01/2018 Broker: BMO Capital Markets Rating: Sell New Target: $1.9 Initiate
11/12/2017 Broker: Northland Capital Rating: Buy New Target: $2.75 Maintain
10/11/2017 Broker: Northland Capital Rating: Buy New Target: $4.5 Maintain

Analysts expect Natera, Inc. (NASDAQ:NTRA) to report $-0.54 EPS on May, 8.They anticipate $0.16 EPS change or 22.86% from last quarter’s $-0.7 EPS. After having $-0.73 EPS previously, Natera, Inc.’s analysts see -26.03% EPS growth. The stock increased 0.36% or $0.04 during the last trading session, reaching $11.26. About 92,508 shares traded. Natera, Inc. (NASDAQ:NTRA) has risen 1.23% since May 3, 2017 and is uptrending. It has underperformed by 10.32% the S&P500.

The stock increased 9.09% or $0.14 during the last trading session, reaching $1.68. About 294,023 shares traded or 141.06% up from the average. Bellatrix Exploration Ltd. (NYSE:BXE) has declined 72.13% since May 3, 2017 and is downtrending. It has underperformed by 83.68% the S&P500.

Bellatrix Exploration Ltd., an oil and gas company, engages in the acquisition, exploration, development, and production of oil and natural gas reserves in the provinces of Alberta, British Columbia, and Saskatchewan in Canada. The company has market cap of $82.68 million. It primarily focuses on developing its two core resource plays, the Cardium and the Notikewin/Falher intervals in Western Canada. It currently has negative earnings.

Among 8 analysts covering Natera Inc (NASDAQ:NTRA), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Natera Inc had 25 analyst reports since July 27, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, July 19 by Cowen & Co. The company was initiated on Tuesday, April 19 by Benchmark. As per Wednesday, March 14, the company rating was maintained by Robert W. Baird. As per Wednesday, March 14, the company rating was maintained by Canaccord Genuity. The firm has “Buy” rating by Benchmark given on Wednesday, May 11. Wedbush upgraded the stock to “Outperform” rating in Monday, September 28 report. Wedbush initiated it with “Neutral” rating and $20 target in Monday, July 27 report. As per Monday, July 27, the company rating was initiated by Morgan Stanley. Cowen & Co initiated Natera, Inc. (NASDAQ:NTRA) rating on Monday, July 27. Cowen & Co has “Outperform” rating and $25 target. The stock has “Overweight” rating by Piper Jaffray on Monday, July 27.

Natera, Inc., a diagnostics company, provides preconception and prenatal genetic testing services. The company has market cap of $610.11 million. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. It currently has negative earnings. The firm also provides products of conception testing under the Anora brand to analyze fetal chromosomes to understand the cause of miscarriage; non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father.

Natera, Inc. (NASDAQ:NTRA) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>